Summit Therapeutics rises after AstraZeneca commits $2B investment (SMMT:NASDAQ)

· seekingalpha.com

Summit (SMMT) and AstraZeneca (AZN) ink a $2B convertible investment plus GI cancer trial collaboration for ivonescimab/ADCs—read key terms now.

Summit (SMMT) and AstraZeneca (ANZ) announced on Monday that the companies have entered into an agreement whereby AstraZeneca will make an equity investment of ...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI